These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31430372)

  • 1. Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
    Del Barrio-Tofiño E; Sánchez-Diener I; Zamorano L; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    J Antimicrob Chemother; 2019 Nov; 74(11):3217-3220. PubMed ID: 31430372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.
    Del Barrio-Tofiño E; Zamorano L; Cortes-Lara S; López-Causapé C; Sánchez-Diener I; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    J Antimicrob Chemother; 2019 Jul; 74(7):1825-1835. PubMed ID: 30989186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones.
    Mulet X; García R; Gayá M; Oliver A
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):541-544. PubMed ID: 30680561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
    J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
    Hernández-García M; García-Castillo M; García-Fernández S; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Romano J; Pássaro L; Paixão L; López-Mendoza D; Díaz-Regañón J; Cantón R;
    J Antimicrob Chemother; 2021 Jan; 76(2):370-379. PubMed ID: 33099623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study.
    Mulet X; Fernández-Esgueva M; Norte C; Zamorano L; Del Barrio-Tofiño E; Oliver A;
    Enferm Infecc Microbiol Clin (Engl Ed); 2021; 39(6):279-282. PubMed ID: 34088448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
    Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
    J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
    Galani I; Papoutsaki V; Karantani I; Karaiskos I; Galani L; Adamou P; Deliolanis I; Kodonaki A; Papadogeorgaki E; Markopoulou M; Maraki S; Damala M; Prifti E; Vagiakou E; Petinaki E; Fountoulis K; Tsiplakou S; Kirikou H; Souli M; Antoniadou A; Giamarellou H
    J Antimicrob Chemother; 2020 Aug; 75(8):2164-2172. PubMed ID: 32449909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
    Arca-Suárez J; Fraile-Ribot P; Vázquez-Ucha JC; Cabot G; Martínez-Guitián M; Lence E; González-Bello C; Beceiro A; Rodríguez-Iglesias M; Galán-Sánchez F; Bou G; Oliver A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
    Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.
    Cabot G; López-Causapé C; Ocampo-Sosa AA; Sommer LM; Domínguez MÁ; Zamorano L; Juan C; Tubau F; Rodríguez C; Moyà B; Peña C; Martínez-Martínez L; Plesiat P; Oliver A
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7415-7423. PubMed ID: 27736752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection.
    Nasrin S; Hegerle N; Sen S; Nkeze J; Sen S; Permala-Booth J; Choi M; Sinclair J; Tapia MD; Johnson JK; Sow SO; Thaden JT; Fowler VG; Krogfelt KA; Brauner A; Protonotariou E; Christaki E; Shindo Y; Kwa AL; Shakoor S; Singh-Moodley A; Perovic O; Jacobs J; Lunguya O; Simon R; Cross AS; Tennant SM
    BMC Microbiol; 2022 Jan; 22(1):13. PubMed ID: 34991476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.